Back HIV/AIDS

HIV / AIDS

IAS 2013: Switch to Etravirine Maintains Viral Suppression and Improves Lipid Levels

People with HIV who switch from their current antiretroviral regimen to the NNRTI etravirine (Intelence) maintain undetectable viral load and may see improvement in metabolic parameters, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.alt

Coverage of the 2013 International AIDS Society Conference

HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.

Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.

Full listing by topic

HIVandHepatitis.com IAS 2013 conference section

7/6/13

alt

 

IAS 2013: Stem Cell Transplant Patients Remain HIV-Free [VIDEO]

Two Boston men with HIV who received bone marrow transplants after a milder conditioning chemotherapy regimen continued to have undetectable virus 7 and 15 weeks after undergoing experimental treatment interruption, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Long-acting GSK1265744 and TMC278-LA Appear Safe and Practical in Early Study

A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries

A second-line regimen consisting of a protease inhibitor (PI) plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) led to good outcomes for people with HIV in Africa after initial regimen failure, according to data from the EARNEST study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. A NRTI-sparing regimen with raltegravir did not work significantly better, and PImonotherapy was inferior.

alt

IAS 2013: First-line Antiretroviral Therapy has Improved Over Time, Meta-analysis Shows

The effectiveness of initial antiretroviral treatment has improved markedly over the years, but many people still do not achieve full HIV suppression and a majority end up going off their initial regimen for various reasons, according to a large meta-analysis presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Boston Stem Cell Transplant Recipients Now Controlling HIV Off Treatment

Two people with HIV who received stem cell transplants to treat lymphoma are now controlling HIV replication without antiretroviral medication in the early weeks of treatment interruption, following the discovery that both had experienced loss of detectable HIV DNA, researchers from Boston reported Wednesday at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.alt